CYP17A1 and Burkitt lymphoma: Interestingly, the three enzymes whose activity was decreased in BL patients were also significantly less active in BL patients presenting an ARMC5 mutation (PBMAH Mut) in comparison to BL patients without any ARMC5 mutation (‘bilateral adenomas’ and ‘WT ARMC PBMAH’ merged into one group under the generic abbreviation ‘BL WT’), the difference being statistically significant for CYP11B1 (P = 0.0357) and CYP17A1-17-alpha-hydroxylase (P = 0.0357) (Supplementary Fig. 9).